Evidence map›Paper›PMID 26805822›Full record

ReviewInternational journal of molecular sciences2016

An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs.

Siddharth Menon, Siny Shailendra, Andrea Renda, Michael Longaker, Natalina Quarto

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Stem cells and their potential clinical applications in psychiatric disorders.Progress in neuro-psychopharmacology & biological psychiatry · 2018
    Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Siddharth MenonHagey Laboratory for Pediatric Regenerative Medicine, Department of Surgery, School of Medicine, Stanford University, 257 Campus Drive, Stanford, CA 94305, USA. smenon8@stanford.edu.
Siny ShailendraHagey Laboratory for Pediatric Regenerative Medicine, Department of Surgery, School of Medicine, Stanford University, 257 Campus Drive, Stanford, CA 94305, USA. sinys@stanford.edu.
Andrea RendaDipartimento di Scienze Biomediche Avanzate, Universita' degli Studi di Napoli Federico II, Napoli 80131, Italy. renda@unina.it.
Michael LongakerHagey Laboratory for Pediatric Regenerative Medicine, Department of Surgery, School of Medicine, Stanford University, 257 Campus Drive, Stanford, CA 94305, USA. longaker@stanford.edu.
Natalina QuartoHagey Laboratory for Pediatric Regenerative Medicine, Department of Surgery, School of Medicine, Stanford University, 257 Campus Drive, Stanford, CA 94305, USA. quarto@unina.it.

Funding

Induced pluripotent stem cells in the understanding and treatment of heart diseaseU01HL099776 · NHLBI · STANFORD UNIVERSITY · PI LONGAKER, MICHAEL T, WU, JOSEPH C. · 2009 to 2015
$8.2M
Osteogenic Enrichment of Adipose Derived Stromal CellsR01DE021683 · NIDCR · STANFORD UNIVERSITY · PI GURTNER, GEOFFREY C, LONGAKER, MICHAEL T · 2012 to 2016
$2.0M
Regional differences in neural crest and mesodermal derived calvarial bone healinR01DE019434 · NIDCR · STANFORD UNIVERSITY · PI LONGAKER, MICHAEL T · 2010 to 2013
$1.5M
NHLBI NIH HHS U01 HL099776NHLBI NIH HHS U01HL099776NIDCR NIH HHS R01 DE019434NIDCR NIH HHS R01 DE021683NIDCR NIH HHS R01 DE021683-01-01NIDCR NIH HHS R01 DE19434
6 · The paper itself

Abstract

Stem cells are classified into embryonic stem cells and adult stem cells. An evolving alternative to conventional stem cell therapies is induced pluripotent stem cells (iPSCs), which have a multi-lineage potential comparable to conventionally acquired embryonic stem cells with the additional benefits of being less immunoreactive and avoiding many of the ethical concerns raised with the use of embryonic material. The ability to generate iPSCs from somatic cells provides tremendous promise for regenerative medicine. The breakthrough of iPSCs has raised the possibility that patient-specific iPSCs can provide autologous cells for cell therapy without the concern for immune rejection. iPSCs are also relevant tools for modeling human diseases and drugs screening. However, there are still several hurdles to overcome before iPSCs can be used for translational purposes. Here, we review the recent advances in somatic reprogramming and the challenges that must be overcome to move this strategy closer to clinical application.

Indexed as

Cellular ReprogrammingAdult Stem CellsBiomarkersCell- and Tissue-Based TherapyCell DifferentiationEmbryonic Stem CellsGene ExpressionGenetic VectorsHumansInduced Pluripotent Stem CellsKruppel-Like Factor 4Kruppel-Like Transcription FactorsOctamer Transcription Factor-3Proto-Oncogene Proteins c-mycRegenerative MedicineSOXB1 Transcription FactorsBiomarkersKruppel-Like Factor 4Kruppel-Like Transcription FactorsMYC protein, humanOctamer Transcription Factor-3POU5F1 protein, humanProto-Oncogene Proteins c-mycSOX2 protein, humanSOXB1 Transcription Factorsadult stemembryonic stem cellsinduced pluripotent stem cells (iPSCs)somatic reprogramming

Identifiers

PMID26805822
PMCPMC4730380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.